Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM)
NASDAQ:AMEX Investor Relations:
ir.actiniumpharma.com
Company Research
Source: PR Newswire
NEW YORK, June 25, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced at SNMMI or the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting that effective lymphodepletion with the radioisotope Lu-177 or lutetium-177 was achieved with its ACT or Adoptive Cell Therapy program for achieving safe, effective and transient lymphodepletion prior to the administration of CAR-T and other adoptive cell therapies. The ARC's or Antibody Radiation-Conjugates used in the ACT program combines a CD45 targeting antibody with the cell killing power of radioisotopes.Lymphodepletion is an important step prior to CAR-T and adoptive cell therapies that facilitates infused cells to engraft, expand and persist. Currently, chemotherapy such as Flu/Cy or Fludarabine and Cyclophosphamide are used in standard practice for lymphodepletion. Patients receiving CAR-T and other adoptive cell therapies are often heavily pre-treated and their cancer i
Show less
Read more
Impact Snapshot
Event Time:
ATNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATNM alerts
High impacting Actinium Pharmaceuticals, Inc. (Delaware) news events
Weekly update
A roundup of the hottest topics
ATNM
News
- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law FirmAccesswire
- Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsPR Newswire
- The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud Accesswire
ATNM
Earnings
- 11/14/24 - Miss
ATNM
Analyst Actions
- 11/15/24 - HC Wainwright
ATNM
Sec Filings
- 11/14/24 - Form 10-Q
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- ATNM's page on the SEC website